Helicobacter Pylori and Gastroesophageal Reflux Disease

Practical Manual of Gastroesophageal Reflux Disease

Volumn , Issue , 2013, Pages 267-285

  Dore, Maria Pina ^a,b   Graham, David Y ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acid secretion; Atrophic gastritis; Barrett's esophagus; CagA; Esophageal adenocarcinoma; Esophagitis; Gastric adenocarcinoma; Gastritis; Gastroesophageal reflux disease; GERD; Helicobacter pylori; Peptic ulcer; Reflux esophagitis

Indexed keywords

EID: 84887145560     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118444788.ch16     Document Type: Chapter

References (80)

1. Axon A, Forman D. Helicobacter gastroduodenitis: a serious infectious disease. BMJ 1997;314:1430-1.
2. Schutze K, Hentschel E, Dragosics B, Hirschl AM. Helicobacter pylori reinfection with identical organisms: transmission by the patients'spouses. Gut 1995;36:831-3.
3. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
4. Winkelstein A, Wolf BS, Som ML, Marshak RH. Peptic esophagitis with duodenal or gastric ulcer. JAMA 1954;154:885-9.
5. Winkelstein A. Peptic esophagitis with duodenal ulcer. Am J Surg 1957;93:234-7.
6. Cruze K, Byron FX, Hill JT. The association of peptic ulcers and asymptomatic hiatal hernia. Surgery 1959;46:664-8.
7. Moraes-Filho JP, Zaterka S, Pinotti HW, Bettarello A. Esophagitis and duodenal ulcer. Digestion 1974;11:338-46.
8. Moraes-Filho JP. Lack of specificity of the acid perfusion test in duodenal ulcer patients. Am J Dig Dis 1974;19:785-90.
9. Flook D, Stoddard CJ. Gastro-oesophageal reflux and oesophagitis before and after vagotomy for duodenal ulcer. Br J Surg 1985;72:804-7.
10. Behar J, Biancani P, Sheahan DG. Evaluation of esophageal tests in the diagnosis of reflux esophagitis. Gastroenterology 1976;71:9-15.
11. Goldman MS Jr, Rasch JR, Wiltsie DS, Finkel M. The incidence of esophagitis in peptic ulcer disease. Am J Dig Dis 1967;12:994-9.
12. Earlam RJ, Amerigo J, Kakavoulis T, Pollock DJ. Histological appearances of oesophagus, antrum and duodenum and their correlation with symptoms in patients with a duodenal ulcer. Gut 1985;26:95-100.
13. Boyd EJ. The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia. Am J Gastroenterol 1996;91:1539-43.
14. Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 2009;44:518-34.
15. Dent J. Review article: from 1906 to 2006-a century of major evolution of understanding of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006;24:1269-81.
16. Graham DY. The changing epidemiology of GERD: geography and Helicobacter pylori. Am J Gastroenterol 2003;98:1462-70.
17. Liu Y, Akiyama J, Graham DY. Current understandings of Helicobacter pylori, peptic ulcer and gastroesophageal reflux disease. Minerva Gastroenterol Dietol 2006;52:235-48.
18. Latrobe CJ. Travels in North America. The American Quarterly Review. Philadelphia: Lydia R. Bailey, 1835: pp. 390-422.
19. West T. Treatise on pyrosis idiopathica or water-brash as contrasted with certain forms of indigestion and of organic lesions of the abdominal organs, together with the remedies dietetic and medicinal. London: Longman, Orme, Brown, Green and Longmans, 1841.
20. Graham DY, Smith JL, Patterson DJ. Why do apparently healthy people use antacid tablets? Am J Gastroenterol 1983;78:257-60.
21. Watanabe T, Urita Y, Sugimoto M, Miki K. Gastroesophageal reflux disease symptoms are more common in general practice in Japan. World J Gastroenterol 2007;13:4219-23.
22. Graham DY. Categories of patients with gastroesophageal reflux. Arch Intern Med 1991;151:2476.
23. Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci 1983;28:559-63.
24. Graham DY. Helicobacter pylori and perturbations in acid secretion: the end of the beginning. Gastroenterology 1996;110:1647-50.
25. Graham DY, Dixon MF. Acid secretion, Helicobacter pylori, and peptic ulcer disease. In: Graham DY, Genta RM, Dixon MF (eds) Gastritis. Philadelphia: Lippincott Williams and Wilkins, 1999: pp. 177-88.
26. Liu Y, Vosmaer GD, Tytgat GN, Xiao SD, ten Kate FJ. Gastrin G. cells and somatostatin D. cells in patients with dyspeptic symptoms: Helicobacter pylori associated and nonassociated gastritis. J Clin Pathol 2005;58:927-31.
27. Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol 2010;45:1-8.
28. Comfort MW. Gastric acidity before and after development of gastric cancer: its etiologic, diagnostic and prognostic significance. Ann Intern Med 1951;36:1331-48.
29. Gutierrez O, Melo M, Segura AM, Angel A, Genta RM, Graham DY. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997;32:664-8.
30. Graham DY, Shiotani A, El-Zimaity HM. Chromoendoscopy points the way to understanding recovery of gastric function after Helicobacter pylori eradication. Gastrointest Endosc 2006;64:686-90.
31. Malaty HM, Kim JG, El-Zimaity HM, Graham DY. High prevalence of duodenal ulcer and gastric cancer in dyspeptic patients in Korea. Scand J Gastroenterol 1997;32:751-4.
32. Ellis FH Jr, Lyons WS, Olsen AM. The gastroesophageal sphincter mechanism: a review. Mayo Clin Proc 1956;31:605-14.
33. Hill LD, Kozarek RA. The gastroesophageal flap valve. J Clin Gastroenterol 1999;28:194-7.
34. Hill LD, Kozarek RA, Kraemer SJ, et al. The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc 1996;44:541-7.
35. Shirota T, Kusano M, Kawamura O, Horikoshi T, Mori M, Sekiguchi T. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J Gastroenterol 1999;34:553-9.
36. Wong WM, Lai KC, Hui WM, et al. Pathophysiology of gastroesophageal reflux diseases in Chinese-role of transient lower esophageal sphincter relaxation and esophageal motor dysfunction. Am J Gastroenterol 2004;99:2088-93.
37. Zerbib F, Bicheler V, Leray V, et al. H. pylori and transient lower esophageal sphincter relaxations induced by gastric distension in healthy humans. Am J Physiol Gastrointest Liver Physiol 2001;281:G350-G356.
38. Tanaka I, Tatsumi Y, Kodama T, et al. Effect of Helicobacter pylori eradication on gastroesophageal function. J Gastroenterol Hepatol 2004;19:251-7.
39. Graham DY. Campylobacter pylori and Barrett's esophagus. Mayo Clin Proc 1988;63:1258-60.
40. Rugge M, Russo V, Busatto G, et al. The phenotype of gastric mucosa coexisting with Barrett's oesophagus. J Clin Pathol 2001;54:456-60.
41. Lanza FL, Graham DY. Bougienage is effective therapy for most benign esophageal strictures. JAMA 1978;240:844-7.
42. Patterson DJ, Graham DY, Smith JL, et al. Natural history of benign esophageal stricture treated by dilatation. Gastroenterology 1983;85:346-50.
43. Benedict EB, Sweet RH. Benign stricture of the esophagus. Gastroenterology 1948;11:618-28.
44. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 1990;98:654-61.
45. Collen MJ, Johnson DA, Sheridan MJ. Basal acid output and gastric acid hypersecretion in gastroesophageal reflux disease. Correlation with ranitidine therapy. Dig Dis Sci 1994;39:410-17.
46. Collen MJ, Jensen RT. Idiopathic gastric acid hypersecretion. Comparison with Zollinger-Ellison syndrome. Dig Dis Sci 1994;39:1434-40.
47. Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999;116:239-47.
48. Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009;137:80-7.
49. McColl KE, Gillen D. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology 2009;137:20-2.
50. Graham DY, Dore MP. Perturbations in gastric physiology in Helicobacter pylori duodenal ulcer: are they all epiphenomena? Helicobacter 1997;2(Suppl 1):S44-9.
51. Nakajima S, Hattori T. Active and inactive gastroesophageal reflux diseases related to Helicobacter pylori therapy. Helicobacter 2003;8:279-93.
52. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003;326:737-9.
53. Qia B, Ma S. Effects of Helicobacter pylori eradication on gastroesophageal reflux disease: evidence from eleven studies. Helicobacter 2011;16(4):255-65.
54. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-6.
55. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001;357:1738-42.
56. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002;97:2992-7.
57. Ishiki K, Mizuno M, Take S, et al. Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal ulcer disease. Clin Gastroenterol Hepatol 2004;2:474-9.
58. Asaka M, Kato M, Graham DY. Strategy for eliminating gastric cancer in Japan. Helicobacter 2010;15:486-90.
59. Asaka M, Kato M, Graham DY. Prevention of gastric cancer by Helicobacter pylori eradication. Intern Med 2010;49:633-6.
60. Graham DY. Gastric cancer surveillance or prevention plus targeted surveillance. Jap J Helicobacter Res 2009;10:9-14.
61. El-Serag HB. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 2002;31:421-40.
62. El-Serag HB, Graham DY. Routine polypectomy for colorectal polyps and ablation for Barrett's esophagus are intellectually the same. Gastroenterology 2011;140:386-8.
63. Hayward J. The lower end of the oesophagus. Thorax 1961;16:36-41.
64. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883-90.
65. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007;5:1413-17.
66. Graham DY. Helicobacter pylori is not and never was "protective" against anything, including GERD. Dig Dis Sci 2003;48:629-30.
67. Kudo M, Gutierrez O, El-Zimaity HM, et al. CagA in Barrett's oesophagus in Colombia, a country with a high prevalence of gastric cancer. J Clin Pathol 2005;58:259-62.
68. Graham DY, Yamaoka Y. H. pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter 1998;3:145-51.
69. Graham DY. The only good Helicobacter pylori is a dead Helicobacter pylori. Lancet 1997;350:70-1.
70. Graham DY. Can therapy ever be denied for Helicobacter pylori infection? Gastroenterology 1997;113 6(Suppl):S113-17.
71. Graham DY, Opekun AR, Yamaoka Y, Osato MS, El-Zimaity HM. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther 2003;17:193-200.
72. Graham DY, Genta RM. Long-term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep 2008;10:543-7.
73. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22.
74. Kuipers EJ, Klinkenberg-Knol EC, Vandenbroucke-Grauls CM, Appelmelk BJ, Schenk BE, Meuwissen SG. Role of Helicobacter pylori in the pathogenesis of atrophic gastritis. Scand J Gastroenterol 1997;223(Suppl):28-34.
75. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989;96:615-25.
76. Lundell L, Havu N, Miettinen P, et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006;23:639-47.
77. Lundell L, Havu N, Miettinen P, Myrvold HE, Wallin L, Julkunen R, et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006;23:639-47.
78. Yang HB, Sheu BS, Wang ST, Cheng HC, Chang WL, Chen WY. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. Am J Gastroenterol 2009;104:1642-9.
79. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004;53:12-20.
80. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56: 772-81.